Especialistas en medicina nuclear y neurólogos del Hospital Clínico San Carlos coordinan un estudio a nivel mundial para el diagnóstico y seguimiento de enfermedades neurodegenerativas, gracias a u...
Read more
The Spanish Agency of Medicines and Medical Devices has authorised the clinical trial of IDP-121, the first drug blocking and degrading a key oncoprotein in several hematological tumors, including mul...
Read more
Un ensayo clínico internacional controlado aleatorizado de Fase I, en humanos, utilizando DIALIVE -un novedoso dispositivo de diálisis hepática-, demostró su potencial como terapia modificadora de...
Read more
Researchers from VHIO's Experimental Hematology Group have participated in the development of a new technology to manufacture CAR-T cells or genetically modified lymphocytes to attack tumor cells, whi...
Read more
A multicentre study led by the Hospital Clínic Barcelona-IDIBAPS demonstrates the efficacy of the CAR T-cell therapy ARI0002h in treating patients with multiple myeloma resistant to standard treatmen...
Read more
Oryzon Genomics today reports new preliminary blinded aggregate safety data from its ongoing Phase IIb PORTICO trial, investigating vafidemstat in Borderline Personality Disorder (BDP).
Read more
Blood-based circulating tumor DNA analysis of plasma samples from patients enrolled in the open-label, randomized phase III VOYAGER clinical trial show that ctDNA sequencing can predict cancer drug re...
Read more
La Fundación ”la Caixa” destinará 4,6 millones de euros a potenciar la investigación en el hospital Clínic Barcelona con el objetivo de desarrollar nuevas terapias personalizadas para diversos...
Read more
The triple effect of obefazimod would make the drug a potential candidate when designing HIV remission strategies
Read more
La Administración de Alimentos y Medicamentos de Estados Unidos (FDA, por sus siglas en inglés) ha aprobado Elevidys, la primera terapia génica para el tratamiento de la distrofia muscular de Duche...
Read more
A research team from IRB Barcelona and the biotech Nostrum Biodiscovery has developed a new type of inhibitor that blocks only some of the functions of the p38 protein. The alternative pathway that th...
Read more
Researcher has been able to verify that the combination of two drugs, enfortumab vedotin and pembrolizumab, which had previously shown benefits in survival in second-line treatment and in cases of adv...
Read more
La mejor actitud que podemos adoptar es la de trat...
The research team observed changes in head circumf...
AtCDF3 gene induced greater production of sugars a...
En nuestro post hablamos sobre este interesante tipo de célula del...
Acute myeloid leukemia (AML) does more than infiltrate the lungs: it a...
